Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:23 PM
Ignite Modification Date:
2025-12-24 @ 7:23 PM
NCT ID:
NCT00302003
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed Hodgkin's lymphoma meeting the following criteria:
* Newly diagnosed disease
* Stage IA OR stage IIA without bulky disease
* No lymphocyte-predominant histology
* Staging on this study will be determined by the clinical stage; surgical staging is strongly discouraged, except for the rare situation of equivocal imaging studies below the diaphragm
* Patients may not have received any previous chemotherapy or radiation therapy; patients may not have received systemic corticosteroids within 30 days of enrollment on this protocol; steroids used for treatment of contrast agent allergy required for computed tomography (CT) scans are acceptable
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^3
* Total bilirubin =\< 1.5 x normal
* Alanine (ALT) =\< 2.5 x normal
* Shortening fraction \>= 27% by echocardiogram OR ejection fraction \>= 50% by multi-gated acquisition (MUGA)
* No pathologic prolongation of QTc interval on 12-lead electrocardiography (ECG)
* Female patients of childbearing potential must have a negative pregnancy test
* Lactating females must agree that they will not breastfeed a child while on this study
* Fertile patients must use effective contraception
* Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
21 Years
Study:
NCT00302003
Study Brief:
Protocol Section:
NCT00302003